International Research Journal of Education and Technology

Chemotherapy‑induced hypertension (C‑HTN) has emerged as a prevalent complication in cancer treatment, particularly with the advent of targeted therapies such as VEGF inhibitors, tyrosine kinase inhibitors (TKIs), proteasome inhibitors, and others. This review examines the underlying risk factors, mechanisms, clinical monitoring strategies, and management protocols. It synthesizes current evidence and guidelines, focusing on optimizing cardiovascular and oncologic outcomes through tailored approaches that balance antihypertensive therapy with oncologic efficacy.